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Abstract
In patients with Type I diabetes mellitus (T1DM) undergoing intensive insulin
therapy, the development of insulin resistance (IR) is linked to the improper storage of
intramyocellular lipid (IMCL) species. While both IR and IMCL are improved with
combined aerobic and resistance training, it is unclear how these adaptations relate to
individual fibre-type transitions and metabolic function. This study aimed to compare the
effects of combined exercise training versus conventional and intensive insulin therapy on
skeletal muscle fibres in T1DM rodents. Seventeen Sprague-Dawley rats were divided into
groups: Control-Sedentary (CS; n=4), conventionally-treated T1DM sedentary (DCT; n=4),
intensively-treated T1DM sedentary (DIT; n=5) and combined aerobic/resistance exercisetrained T1DM (DCE; n=4). After twelve weeks, muscle fibre type, IMCL, and muscle
glycogen content were analyzed. Significant increases in IMCL storage solely in type I fibres
implicate improvements in oxidative capacity rather than a shift towards more oxidative
fibres as the primary mechanism for these improvements.

Keywords
Type 1 diabetes mellitus, exercise, skeletal muscle, intramyocellular lipids, muscle fibre/fiber
type, muscle glycogen, insulin treatment
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Summary for Lay Audience
Type 1 diabetes mellitus (T1DM) is caused by the body’s immune system targeting
and destroying the Beta cells in the pancreas that are responsible for producing insulin.
Therefore, most T1DM patients rely on insulin injections to maintain their blood sugar levels
as close to normal as possible. The traditional (or conventional) insulin therapy consists of
patients injecting insulin once or twice per day, with minimal monitoring of their blood sugar
levels. The use of intensive insulin therapy has lessened the development of cardiovascular
and other diabetes-related complications, though it is associated with the development of
insulin resistance (IR). IR is a condition where injected insulin has a diminishing effect over
time, requiring progressively more insulin to achieve the same reduction in blood sugar. In
the current study, IR development in T1DM is linked to the accumulation of improperly
stored fat within the muscle, which is readily improved with combined endurance and
resistance exercise training. In this thesis we set out further to test whether the improvements
in fat storage were due to a preferential shift in the number of fibres or whether the individual
fibres improved the way they stored the fat. Four groups were studied: 1) healthy but
sedentary rats, 2) well-controlled intensively insulin-treated T1DM rats, 3) poorly-controlled
conventionally insulin-treated T1DM rats, and 4) poorly-controlled conventionally insulintreated T1DM rats that underwent a combined exercise training program. Histochemical
staining was used to determine the type of muscle fibre, and the quantity of both fat and
glycogen stored in these fibres using the mixed-fibre plantaris muscle. The primary finding
of the current study was that both intensive insulin therapy and combined exercise training
led to a significant increase in type I fibres. However, combined exercise led to a
significantly greater increase in type I fibre fat content in comparison to that of the intensive
iii

insulin-treated T1DM group. These findings would indicate that preferential shifts to type 1
fibres are evident following intensive insulin therapy and combined exercise training;
however, exercise training leads to an increase in preferential fat storage to these oxidative
fibres.
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Chapter 1
1.1 Overview and Treatment of Type 1 Diabetes Mellitus
In September of 1925, Dr. Frederick G. Banting gave a lecture to a crowded
room about the landmark discovery of insulin and its miraculous effects on patients with
type I diabetes mellitus (T1DM), for which he and Dr. John Macleod had been awarded
the Nobel Prize in Physiology and Medicine three years prior. Even though a huge step
had been taken towards improving the lives of millions of people worldwide, the message
of his Nobel lecture was not the triumphant celebration one might expect. Rather, Dr.
Banting counselled that expectations must be managed, and that this discovery was by no
means the end of the road for diabetes research. He concluded his lecture with the words
“Insulin is not a cure for diabetes; it is a treatment. It enables the diabetic to burn
sufficient carbohydrates, so that proteins and fats may be added to the diet in sufficient
quantities to provide energy for the economic burdens of life.” 1.
On the surface, it may not seem that a lot has changed since then in terms of our
approach to T1DM treatment. Insulin is still very much a cornerstone of modern T1DM
treatment strategies, and many patients still struggle with balancing optimal insulin
dosage with calorie intake and exercise 2. However, ninety-four years later, we now have
a much better understanding of the pathophysiology of T1DM and the treatment
mechanisms behind the actions of the hormone, insulin.
Diabetes mellitus is an umbrella term primarily used to describe two entirely
independent conditions that both lead to impaired glycemic control, though they can be
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traced back to entirely different causes. In both diseases, the blunted action of insulin
causes chronically raised blood glucose levels (hyperglycemia), which inhibits the body’s
ability to maintain energetic homeostasis. In type 2 diabetes mellitus (T2DM), genetic
and lifestyle factors lead to reduced sensitivity to insulin in the tissues, requiring
progressively larger insulin dosages to elicit the same reduction in blood glucose. This
condition is termed insulin resistance (IR), and as it increases, the pancreas is unable to
produce enough insulin to accommodate rising blood sugar levels, resulting in chronic
hyperglycemia and T2DM 3. It is generally agreed that T2DM is a metabolic disorder that
is heavily influenced by genetic and lifestyle factors, although T2DM can often be quite
manageable with a combination of medication and lifestyle changes 3. In contrast, T1DM
is a condition based on a combination of genetic and environmental factors that
contribute to a destructive autoimmune response within the pancreatic islets. This results
in either a partial or total inability to produce insulin 4, leading to unregulated blood
glucose levels that fluctuate well outside the normal, healthy range. T1DM patients must
supplement themselves with exogenous insulin, or they risk severe sickness and, if left
untreated, death 5–7.
In a normal, healthy body, circulating blood glucose is maintained at a relatively
stable equilibrium of 3-5 mmol/L, balancing glucose influx from the digestive tract and
liver, and the demand-based efflux into the various tissues of the body 8. The diagnosis of
T1DM is made when the patient presents either two fasting blood glucose measurements
of over 7 mmol/L, any single blood glucose reading over 11 mmol/L, or an HbA1c of
³6.5% 9,10. HbA1c is a form of haemoglobin that has been covalently bonded to glucose,
and with chronic hyperglycemia these glycated haemoglobin species occur at higher than
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normal concentrations in the blood. Since red blood cells only have a four-month
lifespan, HbA1c is used as an assessment of a three-month average of glycemic control,
and has become a staple of both T1DM and T2DM diagnoses 4,11. Poor overall glycemic
control is strongly associated with cardiovascular disease (CVD) and is the pivotal point
in T1DM disease management, as with every 1% increase in mean HbA1c, CVD risk
increases by 31% 12.
Despite these many advances in our understanding of T1DM research and
treatment, global prevalence of the disease has continued to increase, particularly in
youth populations, as T1DM has become one of the most frequently occurring chronic
diseases in children 13–16. It is currently estimated that there are 33 million people
worldwide with T1DM 4, each relying on lifelong insulin supplementation, and each
living with increased risk of blindness, amputation, CVD, and a host of other
complications 17–19.
In 1983, the Diabetes Control and Complications Trial (DCCT) set out to
determine whether improved control over blood glucose could delay or even prevent the
vascular complications of diabetes. Specifically, the long-term micro- and macrovascular
outcomes of conventional insulin treatment were compared to outcomes in patients who
utilized a more rigorous intensive insulin treatment, over a ten-year period. The
traditionally used conventional insulin treatment consisted of a bolus of insulin taken
once or twice per day, coupled with daily urine or blood glucose testing. In contrast,
intensive insulin treatment patients monitored their blood glucose levels throughout the
day, adjusting their insulin intake with the goal of maintaining blood glucose levels as
close to the normal range as possible. When the DCCT group published their findings in
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1993, it was clear that intensified insulin treatment would be the recommendation going
forward. Within 6.5 years of the start of the trial, T1DM patients on the intensified study
arm showed a risk reduction of 76% in retinopathy, 34% in kidney disease, and 69% in
neuropathy, as well as improved blood pressure and lipid control relative to those
undergoing conventional insulin treatment 17. Consequently, all study patients were then
transitioned to an intensive insulin treatment regimen. It has since been confirmed that
safely maintaining tight glycemic control as close as possible to a healthy range is
paramount to improving lifestyle and disease outcomes in T1DM patients 2,11,19–21. As a
direct result of the DCCT, intensive insulin therapy with the goal of maintaining nearnormal glycemia has been adopted as the standard of care for T1DM patients.
Patient participants (93%) from the DCCT were recruited into the follow-up
Epidemiology of Diabetes Interventions and Complications (EDIC) study 22. The EDIC
aimed to rectify some of the limitations of the DCCT while continuing to study the longterm effects of early intensive insulin treatment 12,22,23. In the 20 year follow-up to the
initial run of the DCCT, the combined DCCT/EDIC found that the incidence of CVD was
42% lower in patients who had followed the intensive treatment protocol12, though that
number decreased to 30% over the following decade 23. As CVD is the most frequent
cause of mortality and disability in T1DM patients, the continued long-term benefits of
intensive insulin therapy highlight the importance of introducing this treatment as early as
possible to reduce the incidence of CVD throughout the lifespan of T1DM patients 23,24.
Recent advances in modern blood glucose monitoring provide an exciting future
for T1DM care. Continuous glucose monitoring (CGM) systems are able to measure and
record blood glucose levels uninterrupted throughout the day and night, providing
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information on daily glucose fluctuations and how those values are influenced over time
and by everyday activities. They are also an integral part of “artificial pancreas” devices,
an emerging technology that combines CGM with an insulin pump, forming a closedloop blood glucose control system, making it far easier for patients to live normal lives
with well-controlled T1DM 2.

1.2 Type 1 Diabetes Mellitus: Disease Outcomes and
Complications
Before the introduction of insulin therapy, an adult with T1DM had a predicted life
expectancy of approximately two years after diagnosis, while diabetic children were often
not expected to live longer than one year 25. However, since the introduction of insulin
therapy and the associated improvement in glycemic control, the acute mortality of
T1DM has largely been eradicated in parts of the world where insulin is available to
patients. Instead, the majority of patients with well-controlled T1DM only experience
associated comorbidities after many years of living with the disease. In these patients,
chronic hyperglycemia brought about by insufficient insulin (hypoinsulinemia) has been
linked to the development of diabetic retinopathy, myopathy, nephropathy, neuropathy,
and cardiovascular disease 17,18. Though these can each contribute to disability and
mortality for patients with T1DM 22, cardiovascular disease alone represents the most
frequent cause of premature death and disability in T1DM patients worldwide 24,
occurring two and three times as often in men and women with T1DM (respectively) in
comparison to the general population 26–28.
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Although hyperglycemia has received a lot of attention and is associated with many
of the complications of T1DM, hypoglycemia has also been linked to long-term
complications of the disease. The primary risk to patients with T1DM is through the
development of severe hypoglycemia during exercise participation, due to a combination
of the insulin-like action of contracting skeletal muscle, insufficient adjustment of preexercise insulin dose, and reduced counter-regulatory hormonal control 29,30.
Additionally, those patients with T1DM who have experienced repeated severe
hypoglycemic events were found to have a higher prevalence of CVD and were
associated with increased mortality from all causes 31,32.

1.3 Skeletal Muscle and Type 1 Diabetes Mellitus
Skeletal muscle is the most adaptable tissue in the body, due in no small part to its
composition of highly specialized fibres, each with different characteristics meant to
thrive under certain circumstances, in specific metabolic environments. As a whole,
skeletal muscle plays a vital role in glucose homeostasis as the primary glucose sink in
the body, acting as the final destination for approximately 80% of the glucose circulating
in the bloodstream 33,34.
Metabolism within the skeletal muscle is driven by energy supply and demand, where
the term “energy” here refers to the generation and breakdown of adenosine triphosphate
(ATP). The muscle derives ATP primarily from a balance of glucose and lipids, adapting
the relative fuel mix to meet the demands of the activity (although in certain situations,
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such as starvation, protein can also be metabolized to provide energy). Typically, lower
intensity activity requires a higher percentage of lipid-derived ATP, whereas higher
intensity energetic demands require a higher percentage of carbohydrate-derived ATP.
The most obvious distinction between the energy source metabolism requirements is the
presence or absence of oxygen, defining aerobic and anaerobic processes.
The primary anaerobic vehicle within the skeletal muscle is through the rapid
dephosphorylation of phosphocreatine paired with the conversion of adenosine
diphosphate (ADP) to ATP. This reaction supplies the muscle with enough ATP for
short-term contraction, fueling exercise bouts of approximately 12 seconds in duration.
While this is occurring, glycogen is being broken down into glucose and then glucose-6phosphate so that it can enter another anaerobic process, glycolysis. Glycolysis partially
catabolizes glucose, providing a quickly available ATP source in the early stages of
exercise and in the absence of oxygen. These two metabolic processes occur in the
cytosol of the muscle fibre, close to the contractile fibres and thus are especially quick to
respond to contraction.
Aerobic respiration, however, takes place in and along the inner membrane of the
mitochondria. The tricarboxylic acid (TCA) cycle takes place in the mitochondrial
matrix, the innermost chamber of the mitochondrion, where acetyl-CoA is enzymatically
broken down and coupled to the protonation of NAD+ and FADH+. These two proton
carrier molecules are created both by glycolysis and the TCA cycle and are used in the
electron transport chain to create a proton gradient across the inner mitochondrial
membrane, which powers ATP synthase and is the most efficient metabolic contributor of
ATP of all the metabolic processes in the muscle.
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Each of the fibre types in skeletal muscle are specialized to support one of these
energy processes above. Type I slow-twitch oxidative fibres have increased
mitochondrial number and volume, while expressing greater activity of enzymes known
to play crucial roles in aerobic metabolic pathways. These fibres also incorporate a
greater number of capillaries per muscle fibre, improving muscle oxygen supply and
aerobic efficiency. In contrast, type IIb fast-twitch glycolytic fibres rely primarily on
anaerobic metabolism as their energy source. While type IIb fibres exhibit lower
mitochondrial number in comparison to type I, cross-sectional area and contractile fibre
size are significantly higher, allowing more forceful and quicker contractions. Type IIa
fast-twitch oxidative fibres occupy a middle ground between the two extremes,
combining fast-twitch contractile fibres with a moderate level of oxidative capacity.
In T1DM, skeletal muscle plays an especially important role as the major downstream
contributor to systemic glycemic control. Since it acts as the primary target for insulin
therapy and is responsible for the majority of insulin-stimulated glucose utilization in the
body, skeletal muscle dysfunction can lead to significant short- and long-term
complications for patients with T1DM, whereas maintaining skeletal muscle health can
help postpone and even alleviate some of the impact of the disease. This is complicated
by the fact that T1DM is known to have a differential effect on the various types of
skeletal muscle fibres, as each type has distinct morphological, contractile, and metabolic
properties 35–37.
It has been known for some time that chronic T1DM is associated with a decline in
metabolic markers within the three major skeletal muscle fibre types. Type I fibres tend
to express selectively reduced markers for oxidative metabolism such as citrate synthase
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activity 37,38, which has been linked to changes in mitochondrial morphology. This
includes fewer mitochondrial cristae, which are the site of the electron transport chain
and therefore the location of many vital oxidative enzymes 35,36. Type IIa fibres
demonstrate a decline in both oxidative and glycolytic markers, exhibiting a combination
of the metabolic and morphological changes observed in the type I and IIb fibres 36–38.
The T1DM related reduction in mitochondrial oxidative enzymes that occurs in the type I
and IIa fibres is not seen in the type IIb fibres. Rather, type IIb fibres tend to express
reduced glycolytic marker enzyme activity, including HK, PFK, and PHOS enzyme
expression 37. As type IIb fibres do not rely on mitochondrial respiration as heavily as do
type I and IIa fibres, the partial loss of mitochondrial oxidative enzymes does not affect
them to the same extent, resulting in type IIb fibres’ reduced susceptibility to the serious
limitations in metabolic capacity brought on by T1DM. However, this is not to say that
type IIb fibres are relatively unaffected by T1DM, or that the changes brought about
exclusively affect metabolic function. The presence of T1DM has been shown to
adversely affect skeletal muscle mass across all fibre types, as well as preferentially
reducing type IIb muscle fibre cross-sectional area 39–42.
While this preferential inhibition of oxidative metabolism in T1DM muscle fibres
may lead to a metabolic bias favouring muscle fibres that rely on glycolytic over
oxidative metabolism, it has been shown that T1DM combined with conventional insulin
treatment opposes these changes and is able to maintain relatively normal function of
many metabolic enzymes in type I, IIa, and IIb fibres 35,37. Furthermore, T1DM muscle
exposed to regular aerobic exercise has been shown to normalize many of these
metabolic enzyme activities across all fibre types independent of but similar to
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conventional insulin therapy 37, suggesting that exercise training may confer benefits
specialized to the T1DM-related metabolic dysfunction found in individual fibre types.
However, the majority of these studies that included the effects of insulin treatment on
specific muscle fibre types have only examined the effects of conventional insulin
therapy 35–37,43, and thus may have limited applicability to the current standard of
treatment relying primarily on intensive insulin therapy. Further study is still required as
there is a noticeable shortage of research examining the way intensive insulin therapy
interacts with the individual skeletal muscle fibre types in T1DM.

1.4 Intramyocellular Lipids (IMCL), the Development of
Insulin Resistance, and Type 1 Diabetes Mellitus
Although the DCCT/EDIC trials have provided extensive and convincing evidence
supporting intensive insulin therapy as an improvement over conventional insulin
treatment, it remains unclear whether this approach is the ideal treatment strategy to
reduce the incidence of cardiovascular disease in T1DM. In some cases, intensive insulin
treatment has led to the development of insulin resistance (IR), a potentially catastrophic
development for insulin-dependent T1DM patients, and a condition more commonly
associated with T2DM 44. Though IR can occur in any of the tissues of the body, the
major contributor to metabolic dysfunction in patients with T1DM is skeletal muscle IR,
due to the major role that skeletal muscle plays in glycemic control. In this scenario,
skeletal muscle IR leads to significantly impaired tissue glucose utilization, followed by a
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compensatory effort to control blood glucose with heightened levels of circulating insulin
(termed hyperinsulinemia), and eventually chronic hyperglycemia 44–46.
The combination of T1DM and at least some level of IR occurs in approximately 20%
of patients with T1DM 47,48. These patients have been referred to as having “double
diabetes”, an unofficial diagnosis that refers to the fact that these patients simultaneously
demonstrate key characteristics of both T1DM and T2DM 49. As one might expect, this
combination of being both dependent on yet resistant to exogenous insulin is highly
dangerous, and these patients have significantly higher incidence of CVD and other
associated disease complications than patients with either T1DM or T2DM alone 44,49–51.
Although the majority of IR-related research has been focused on T2DM and the
development of metabolic syndrome, the presence of IR in T1DM has recently been
recognized as being pathologically different from these other IR-related conditions, and
intensive research efforts are required to elucidate the mechanisms behind this dangerous
combination 51,52. Interestingly, IR and metabolic syndrome have both been recently
identified as better predictors of the incidence of lifetime cardiovascular disease than
HbA1c, the gold standard of T1DM diagnosis criteria 50. In fact, while HbA1c was shown
to lack any predictive power for coronary artery disease, IR has been linked with a
number of factors that predict CVD, and has demonstrated a strong association with the
incidence of coronary artery disease in adults with T1DM 53,54.
The etiology of IR in T1DM is still widely unknown, though support for the
lipotoxicity theory of IR has been steadily gaining support 45,48,55,56. This theory
postulates that IR is caused by the improper storage and subsequent accumulation of
certain IMCL metabolites that lead to interference in the insulin receptor signalling
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pathway, reducing the insulin-related reduction in blood glucose and ultimately
contributing to chronic hyperglycemia 45,48. Evidence has suggested that this
accumulation of IMCL is caused by insufficient insulin levels (hypoinsulinemia) leading
to an increase in lipid flux within the skeletal muscle. The mitochondria are unable to
accommodate this increased lipid metabolism, which leads to a metabolic “overload”, in
which free fatty acids are converted to diacylglycerol (DAG) or metabolized into
ceramides instead of the well-tolerated triacylglycerol (TAG), which has been shown not
to interfere with insulin signalling 48,57,58. This metabolic dysfunction feeds back upon
itself, as the body’s growing accumulation of DAG, ceramides, and a number of IMCL
species has been shown to interfere with insulin signalling, leading to the promotion of
IR in skeletal muscle (Figure 1) 19,46,48.
Previously, our laboratory has demonstrated that the accumulation of certain IMCL
metabolites (including DAG, ceramides, arachidonic acid, linoleic acid, and palmitic
acid) were shown to inhibit various elements of the insulin signalling pathway 48. The
most heavily implicated of these is DAG, which is a transitional lipid species in the
conversion of free fatty acids to TAG, and has been linked with IR through its
interference with the PKC-q component of the insulin signalling pathway (Figure 1) 59,60.
Ceramides are a precursor to several predominant cellular sphingolipids, and have been
implicated as a contributing factor to IR in metabolic syndrome and T2DM by acting on
PKCz (protein kinase C zeta) 61. Arachidonic acid is a polyunsaturated fatty acid
precursor to a number of cytokines responsible for promoting inflammation, and many of
these cytokines have been directly linked with the development of IR 62. Linoleic acid is
another polyunsaturated fatty acid, and has been associated with IR through the reduction
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of muscle GLUT4 protein expression 63. Finally, palmitic acid, among other saturated
fatty acids, contributes to IR through the inhibition of IRS-1 and PKB/Akt
phosphorylation, a key step in the insulin signalling response 64. Our lab has previously
shown that not only are all these IMCL species higher in T1DM rats when compared to
control animals, but that 10 weeks of aerobic exercise training significantly reduces
skeletal muscle DAG, arachidonic acid, linoleic acid, and palmitic acid content
concomitant with significant improvements in insulin sensitivity in T1DM rodents 48.
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Figure 1: The lipotoxicity theory of insulin resistance. Free fatty acids enter the cell via
FAT/CD36 and are shuttled into two main pathways: free fatty acids can enter the
mitochondrial matrix and undergo beta oxidation; or transition to lipid droplets and
where they are stored as TAG. Improper metabolic and structural adaptations that are
unable to accommodate increased lipid flux lead to enhanced fat storage, as well as the
incomplete transition of fatty acids to TAG, leading to increased DAG. DAG has been
shown to activate PKC-q, which in turn inhibits IRS-1. Inactivation of IRS-1 has been
shown to disrupt the insulin signalling pathway, leading to increased insulin resistance.
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1.5 Hypoglycemia and Exercise in Patients with Type 1
Diabetes Mellitus
A regular course of physical activity has been positively associated with many
benefits for almost all populations, T1DM patients included 65. Unfortunately,
participation in exercise training in this particular population is limited by the reasonable
fear of post-exercise hypoglycemia (low blood sugar) 65. In fact, any adjustment to
insulin dose in T1DM patients is, more often than not, based on blood glucose monitoring
and the desire to avoid post-exercise hypoglycemia 66. There is some evidence that
increasing carbohydrate intake and reducing insulin dosage prior to exercise may be a
suitable approach to preventing exercise-induced hypoglycemia 66.
Post-exercise hypoglycemia is postulated to occur due to increased glucose uptake
in exercising skeletal muscle caused by the contraction-mediated translocation of GLUT4
independent of insulin, combined with the additional impact of residual exogenous
insulin circulating in the blood from normal, ongoing T1DM insulin supplementation 67.
This combination can cause a rapid and significant drop in blood glucose, and in extreme
cases can lead to diabetic coma and death 5,31. Another contributing factor may be that
certain patients with T1DM may have a history of poor glycemic control, and therefore
may not have built up the hepatic glycogen stores to the extent where the liver is able to
counteract hypoglycemia 68. There is also evidence that many T1DM patients have a
blunted glucagon response coupled with diminished clearance of injected insulin, which
would contribute to excessively low blood glucose as well 66.
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Despite the risk of hypoglycemia, regular physical activity is positively associated
with a wide range of health benefits for patients with T1DM 69, including reduced serum
cholesterol, higher cardiorespiratory fitness, improved vascular health, enhanced body
composition measures, and a higher quality of life 19,70. Exercise training also decreases
total cholesterol levels in T1DM patients, which is an outcome associated with reduced
risk of CVD 19. Approximately 15% of children with T1DM have elevated LDL-c levels,
which is concerning because not only total cholesterol, but specifically LDL-c is a wellestablished risk factor for CVD itself 71. Patients with T1DM who regularly engage in
exercise training are also reported to have significant benefits including improved aerobic
fitness (VO2max), reduced HbA1c, reduced daily insulin dosage, reduced total
cholesterol 24, and cardiovascular health benefits independent of changes to body
composition. It has also been shown that aerobic fitness is inversely related to CVD risk
and mortality from any cause in T1DM patients 29, lending support to the claim that
regular exercise training provides holistic benefits to the T1DM patient, beyond
metabolic markers. The benefits of regular exercise training far outweigh the risks to
patients living with T1DM, as long as exercise-related risks are suitably planned for,
mitigated, and monitored, in particular the risk of exercise-related hypoglycemia 72.
Aerobic exercise has received a lot of attention in T1DM research, as it is has
been shown to improve oxidative capacity, muscle capillarization, and mitochondrial
density, each of which alone would have profound metabolic benefits for patients with
T1DM 73. It has been demonstrated that aerobic exercise is effective at reducing the
changes that occur preferentially within the type I and IIa oxidative muscle fibres,
opposing the diabetes-induced inhibition of mitochondrial oxidative enzymes and
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contributing to a shift towards improved oxidative capacity throughout the muscle 37.
There is evidence that these exercise-related adaptations are not only due to changes in
metabolic activity within the various muscle fibres but are also due to the ability of
certain fibres to change between primarily oxidative IIa and glycolytic IIb fibre types, as
evidenced by changes in the expression of myosin heavy chain isoforms specific to each
fibre type. While shifts between slow and fast-twitch fibre types have been recorded in
studies of laboratory rats, there is limited evidence that human skeletal muscle is able to
switch between type I and II, whereas fibre type shifting between type IIa and type IIb is
far more common 74.
Recent evidence would indicate that a combined anaerobic and aerobic exercise
training regimen could help to reduce the risk of post-exercise hypoglycemia, making
exercise more accessible to those patients with T1DM who might otherwise entirely
avoid exercise participation, and allowing them access to the benefits of regular exercise
training 21,65,75. In addition, combined exercise training has been shown to cause a number
of changes within the skeletal muscle that confer significant benefits to the insulin
resistant T1DM patient. In healthy subjects, combined exercise training improves upon
both aerobic and resistance training with significantly improved mitochondrial oxidative
capacity in the skeletal muscle, as indicated by increased citrate synthase activity 76,77.
Our lab has extended this line of research to examine whether combined exercise
training could improve upon skeletal muscle oxidative capacity and lipid metabolism
better than aerobic exercise training alone. We found that not only did combined training
improve skeletal muscle citrate synthase activity (and therefore oxidative capacity) better
than aerobic training only, but combined exercise also caused a greater increase in lipid
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storage capacity within the muscle than aerobic exercise training did via reduced CD36
and increased Lipin-1 56. This indicates that the muscle’s various adaptations to combined
exercise allows for increased lipid storage, so the muscle can more effectively
accommodate the metabolic overload that initially led to the accumulation of insulindesensitizing IMCL species. Between the improved lipid storage and the increased
oxidative capacity, combined exercise-trained skeletal muscle is able to funnel IMCL
towards oxidation and proper IMCL storage as TAG, rather than allowing IMCL to
contribute to cellular signalling disruption through the accumulation of DAG. Improving
the TAG:DAG storage ratio within the muscle provides a mechanism for both the
reduction of IR with combined exercise, and the Athlete’s Paradox observation of
increased overall IMCL storage within the trained muscle.
Combined exercise has also been shown to more effectively maintain muscle
mass across all fibre types than resistance or aerobic exercise alone, including improved
cross sectional area and maintenance of hypertrophy in type IIb glycolytic fibres 39. These
improvements in insulin sensitivity, muscle fibre profile, oxidative capacity, and IMCL
storage in combination with the vital reduction in post-exercise hypoglycemia contribute
to the fact that many physicians, organizations, medical associations, and ministries
currently recommend a regimen of combined aerobic and resistance exercise as the ideal
exercise training modality for patients with T1DM 6,78–80.
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1.6 Rationale
The leading cause of mortality in T1DM patients is CVD, a condition which has been
closely linked with the development of IR in patients undergoing intensive insulin
therapy. Studying the pathophysiology of IR in intensively insulin-treated T1DM patients
is therefore critical to understanding the development of CVD and improving the longterm outcomes for this population. The development of IR is postulated to stem from the
improper storage of IMCL within the skeletal muscle, leading to the accumulation of
lipid metabolites that interfere with the insulin receptor signalling pathway, blunting the
action of insulin and reducing glycemic control. Exercise has been shown to reduce the
buildup of these harmful IMCL species, which has occurred concomitantly with
improvements in insulin sensitivity. However, many T1DM patients avoid exercise due
to the risk of post-exercise hypoglycemia. A combined aerobic and resistance training
regimen has been shown to not only reduce that risk, but also confers significantly
improved benefits to the skeletal muscle than either aerobic or resistance training alone,
including improved oxidative capacity and IMCL storage in the muscle as a whole.
However, it is still unknown how combined exercise training affects individual fibre type
transitions and metabolic function.

1.7 Purpose and Hypothesis
The purpose of this study was to examine the effects of a combined aerobic and
resistance training regimen versus intensive insulin therapy on skeletal muscle fibre
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profile in Streptozotocin (STZ)-induced T1DM rodents. Specifically, we investigated
whether combined exercise led to a transition towards a more oxidative fibre profile,
concomitant with improved IMCL content and stored muscle glycogen. Firstly, we
hypothesized that a regimen of intensive insulin treatment would cause a shift in muscle
fibre type towards a higher percentage of type IIb fibres with high IMCL content.
Secondly, we hypothesized that a combined aerobic and anaerobic exercise training
regimen would lead to a reduction in IMCL stores within type IIb fibres, and an overall
shift in fibre composition towards an increased type IIa fast-twitch and type I slow-twitch
oxidative fibre profile.
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Chapter 2
2.1 Introduction
Type I diabetes mellitus (T1DM) is an autoimmune-related disorder
characterized by the destruction of insulin-producing beta cells in the pancreatic islets of
Langerhans. This results in chronically low levels of circulating insulin and the
subsequent loss of glycemic control. The inability to maintain blood glycemic
equilibrium can result in elevated blood glucose levels, cumulating in a condition known
as hyperglycemia. Over time, uncontrolled hyperglycemia can lead to a host of health
complications. These include the development of cardiovascular disease (CVD),
neuropathy, retinopathy, myopathy, and nephropathy, which represent the greatest
contributors to morbidity and mortality for patients with T1DM 1–3. Despite the many
advances made in T1DM research since the discovery of insulin, global prevalence of the
disease has continued to rise, particularly in youth populations 1. As of 2018, T1DM was
one of the most frequently diagnosed chronic diseases in children and youth 4, and it is
expected to continue to increase in prevalence.
With the publication of the Diabetes Control and Complications Trial (DCCT) in
1993, a large amount of evidence supported the long-term benefits of intensive insulin
therapy over conventional insulin therapy 2. This observation ultimately led to the early
completion of the DCCT trial and recommendation that all future patients with T1DM
utilize an intensive insulin treatment 2. Since then, further research efforts have confirmed
that focusing on tight blood glucose management through intensive insulin therapy
significantly improves lifestyle, longevity, and disease outcomes in patients with T1DM.
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Specifically, intensive insulin therapy leads to significant reductions in the long-term
development of CVD (42%), nephropathy (34%), retinopathy (76%), and neuropathy
(69%) in patients with T1DM 5–11.
In approximately 20% of patients with T1DM, long-term reliance on intensive
insulin therapy has been associated with the development of insulin resistance (IR), a
phenomenon more commonly associated with type 2 diabetes mellitus (T2DM) 12.
Termed “double diabetes”, these patients are at an increased risk for CVD and other
associated morbidities in comparison to patients with either T1DM or T2DM alone 13,14.
Though the majority of IR-related research has been focused on patients with metabolic
syndrome or T2DM, recently the presence of IR in T1DM has been recognized to be
pathologically different from other IR-related conditions 14,15. The pathogenesis of IR in
T1DM in this already high-risk population remains unknown. Thus, research examining
the mechanisms of IR development in patients with T1DM and exploration of
interventional tools to mitigate its onset have recently become an emerging area of study.
One of the more promising theories to be postulated surrounding the development
of “double diabetes” in T1DM is called the muscle-lipotoxicity theory of IR 12,16–18.
Initially proposed as a cause for IR development in T2DM, the theory posits that the
improper storage of intramyocellular lipid (IMCL) metabolites in the skeletal muscle
leads to the disruption of insulin receptor signalling function. As a consequence,
inadequate insulin-mediated reduction in blood sugar occurs leading to sustained
increases in blood glucose and chronic hyperglycemia 16. At the onset of the condition, it
is believed that insufficient levels of insulin lead to an increase in lipid flux which the
mitochondria are unable to accommodate. This “metabolic overload” ultimately results in
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the conversion of free fatty acids into diacylglycerol (DAG), or the metabolization into
ceramides 19. The resulting accumulation of IMCL initiates the development of IR, as
both DAG and ceramides have been shown to interfere with the insulin signalling
pathway 20,21 and have been positively correlated with IR severity 12.
Though the lipotoxicity theory currently carries the most weight, there are other
theories surrounding the development of IR in T1DM. It has been proposed that IR
develops as a direct result of the autoimmune related mechanisms surrounding T1DM,
while other theories focus on glucotoxicity and the accumulation of advanced glycation
end products 22. Moreover, IR develops through increased glucotoxicity in the muscle
cell, leading to the activation of protein kinase C through the activity of c-Jun N-terminal
kinase, which then contributes to inhibition of the insulin signalling pathway 16.
The majority of research regarding muscular adaptations to T1DM has included
markers of metabolic function gathered from whole skeletal muscle. While this work has
shown that T1DM leads to significant decreases in muscle oxidative capacity 23, only a
few studies have examined differential changes in metabolic function between the three
major muscle fibre types 24. In T1DM skeletal muscle, type I slow-twitch oxidative fibres
displayed significantly reduced citrate synthase activity, a marker for oxidative
phosphorylation, which is often associated with changes in mitochondrial morphology
24,25

. Type IIa fast-twitch oxidative fibres exhibit a combination of reduced enzymatic

activity for both oxidative and glycolytic processes in patients with T1DM 24–26. Type IIb
fast-twitch glycolytic muscle fibres of patients with T1DM express reduced enzymatic
activity for markers of glycolytic flux, including hexokinase (HK), phosphofructokinase1 (PFK), and phosphatase (PHOS) 24. Since type IIb fibres do not rely on oxidative

36

phosphorylation to the same extent as types I and IIa, the T1DM-related inhibition of
oxidative capacity has a lesser effect on type IIb fibres. However, it has been shown that
T1DM leads to a preferential reduction in type IIb fibre cross-sectional area (CSA),
resulting in a decrease in the overall skeletal muscle mass 23,27–29.
Regular physical activity has been positively associated with a host of benefits for
patients with T1DM, including increases in overall muscle mass and muscle fibre CSA,
and the normalization of altered metabolic enzyme function 24,30. These changes are
evident across all fibre types, suggesting that exercise may confer both whole-muscle
benefits as well as fibre type-specific changes. Though exercise training in the T1DM
patient population has these muscular benefits, actual participation in this healthy
behaviour is limited by the fear of post-exercise hypoglycemia (low blood sugar) 31.
Hypoglycemia onset following exercise occurs due to the reliance on circulating
exogenous insulin and the increased glucose uptake in skeletal muscle long after the
cessation of exercise. In extreme cases, recurrent or overly prolonged exercise can lead to
acute cognitive dysfunction, diabetic coma and even death. In an effort to avoid this,
many patients (and especially those utilizing a more conventional insulin treatment
regimen) attempt to counter the anticipated exercise-related drop in blood sugar by
reducing their insulin dosage and elevating their blood glucose through carbohydrate
intake prior to the onset of exercise. However, the safety of intentionally elevating blood
glucose levels is questionable, and exercising patients with T1DM who follow this trend
tend to have increased HbA1C values in comparison to sedentary T1DM patients 32.
Recent evidence has shown that with a combined aerobic and resistance exercise
training regimen, this post-exercise hypoglycemia risk can be reduced 9,33. Additionally,
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when compared to aerobic or resistance training alone, combined exercise training
confers many improved benefits to the patient with T1DM. Our laboratory has recently
shown that the combination of aerobic and resistance exercise training improves skeletal
muscle oxidative capacity and maintains muscle mass across all fibre types better than
aerobic or resistance exercise alone 18,27. Interestingly, combined exercise training also
led to a greater reduction in skeletal muscle DAG than aerobic or resistance exercise
alone, which was associated with improvements in IR and suggests that combined
training may be the ideal exercise modality for patients with T1DM 12. Further research
efforts are needed to investigate the specific transitional and metabolic changes to muscle
fibre types resulting from combined exercise in T1DM skeletal muscle. Moreover, these
ongoing studies need to explore these exercise-related changes in skeletal muscle
morphology in comparison to the modern standard of care, intensive insulin therapy.
The purpose of this study was to examine the effects of a combined exercise
training regimen versus intensive insulin therapy on the skeletal muscle fibre profile of
T1DM rodents. Specifically, we investigated whether combined exercise led to a
transition towards more oxidative type I fibres, concomitant with improved
intramyocellular lipid content and stored muscle glycogen content. Firstly, we
hypothesized that a regimen of intensive insulin treatment would cause a shift in muscle
fibre type towards a higher percentage of type IIb fibres with high intramuscular fat
stores. Secondly, we hypothesized that a combined aerobic and anaerobic exercise
training regimen would oppose this change, leading to a reduction in IMCL stores in type
IIb fibres, and a shifting of fibre type towards an oxidative type I and IIa fibre profile.
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2.2 Materials and Methods
2.2.1 Ethics Approval
The protocols in this study were approved by the University Council of Animal
Care of Western University (London, Ontario, Canada) in accordance with the standards
of the Canadian Council on Animal Care.
2.2.2 Animals
Seventeen male Sprague-Dawley rats were obtained from Charles River
Laboratories (St. Constant, Quebec, Canada) at eight weeks of age. The rats were caged
in pairs and held on a consistent 12-hour dark/light cycle, with room temperature held at
20 ± 1°C and relative humidity at 50% for the duration of the study. All rats were given
access to standard rat chow and water ad libitum throughout the study.
2.2.3 Experimental groups
Each rat was randomly assigned into one of four treatment groups. Control
sedentary (CS; n=4), diabetic sedentary with conventional insulin therapy (DCT; n=4),
diabetic sedentary with intensive insulin therapy (DIT; n=5), and diabetic with combined
exercise training and conventional insulin therapy (DCE; n=4).
2.2.4 Experimental Procedures
2.2.4.1 T1DM Induction and Insulin Pellet Implantation
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Following five days of acclimatization, the rats in the three diabetes groups were
given an intraperitoneal low dose injection of 20mg/kg streptozotocin (STZ; SigmaAldrich) every day for five days, in order to induce T1DM. All STZ injections were
given within five minutes of preparation, dissolved in a 0.1 M citrate buffer (pH 4.5).
T1DM was confirmed using non-fasted blood glucose measurements of ³18 mmol/L on
two consecutive days. Following T1DM confirmation, abdominal subcutaneous insulin
pellets were surgically implanted into the three diabetic groups of rats receiving insulin
therapy (1 pellet; 2U insulin/day; Linplant, Linshin). The intensity of insulin therapy was
controlled through addition or removal of insulin pellets as needed, so that DCT rats were
able to maintain a blood glucose range of 9-15 mmol/L, DIT rats were maintained at
blood glucose range of 7-9 mmol/L, and DCE were maintained at BG range of 9-15
mmol/L. Blood glucose ranges were maintained throughout the duration of the study.
2.2.4.2 Exercise Training Protocols
Rats in the DCE experimental group spent a week becoming familiar with the
exercise equipment and then proceeded to undergo a combined regimen of aerobic and
resistance exercise training over the next 12 weeks. Combined resistance and aerobic
exercise training involved alternating for five days per week for 12 weeks, where the first
week would have resistance (R) training performed three days of the week, alternating
with two days of high-intensity aerobic (A) exercise (R-A-R-A-R), followed by a week of
the opposite (with three days of aerobic exercise separated by two days of resistance
exercise; A-R-A-R-A).
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Familiarization with the aerobic exercise protocol was established through
running for 15 minutes at progressively higher speeds on a motorized treadmill (up to
30m/min at a 0° incline) at five and three days before the start of training. The high
intensity aerobic training program involved the DCE rats running for one hour at
27m/min on a 6% incline gradient, eliciting an exercise intensity of between 70-80% of
VO2max 36. The rats were encouraged to maintain pace by short bursts of compressed air
triggered when a rat slowed and broke a photoelectric beam at the back of the treadmill.
Resistance exercise training was accomplished with a weighted ladder climb. At
the top of the ladder was an open, dark box where the rats could shelter. Weights were
placed into small fabric bags attached to the base of their tails and the rats were then
placed on the bottom of the ladder so they could climb. This process was repeated with
increasing weights as the rats adapted to each weight load, in order to maintain
appropriate stimulus to the muscle so as to reproduce a resistance training protocol.
Familiarization involved 10 ladder climbs with progressive weight increases up to 35% of
body mass at 5 and 3 days before the onset of training. Following each climb, the rats
were permitted to rest in the box for ~2 minutes. Pre-training maximal carrying capacity
was determined by initial loading of 75% body mass, with each subsequent climb adding
30g of weight until animals were unable to successfully complete the climb to the
preferred dark box destination at the top of the ladder. During training, the DCE rats were
loaded with 50%, 75%, 90%, and 100% of their predetermined maximal carrying
capacity for single climbs, and then repeated 100% load climbs until exhaustion or
unwillingness to climb despite pressurized air bursts to encourage climbing. Maximal
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carrying capacity was re-evaluated every four exercise sessions to ensure the rats were
undergoing a progressive resistance exercise regime.
2.2.5 Experimental Measures
2.2.5.1 Body Weights, Blood Glucose
Body weights were measured and recorded weekly throughout the course of the
study. Blood glucose measurements were also made weekly throughout the study and
were taken by collecting a small droplet of blood (~50µL) from the saphenous vein.
Blood glucose values were analyzed via a Freestyle Lite Blood Glucose Monitoring
System (Abbot Diabetes Care, INC.) and reported in millimoles per litre (mmol/L).
2.2.5.2 Tissue Collection
Rats were sacrificed 72 hours following their last training session via
anaesthetization with isoflurane, followed by cardiac exsanguination. The lower limbs
were dissected and the plantaris muscles were removed, mounted in CryomatrixÔ
embedding medium (Lot No. 225229, Thermo Fisher Scientific) and rapidly frozen in
isopentane cooled to -70°C by liquid nitrogen. Plantaris was chosen due to its 50:50 mix
of red and white muscle tissue, with the intention of highlighting any changes to both
oxidative and glycolytic fibre types. Serial cryosections were cut in varying thicknesses
(depending on the requirement for the histochemical analysis) at -20°C with a Leica
CM350 Cryostat (Leica Biosystems) and adhered to VWR Superfrost® Plus Microslides
(Cat. No. 48311-703, VWR International). All sections were stored at -30°C until
analysis.
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2.2.6 Histochemical Analysis
2.2.6.1 Hematoxylin and Eosin
Slides were incubated in Harris Haematoxylin for 20 minutes, then rinsed in an
alkaline tap water substitute and exposed to 1% HCl in 70% ethanol for 10 seconds.
Following another rinse in the alkaline tap water, slides were incubated for 3 minutes in a
5% eosin hematology solution. Slides were rinsed in tap water to remove excess stain,
dehydrated in ascending alcohol, cleared with xylenes, and mounted with toluene-based
mounting media.
2.2.6.2 Metachromatic myosin ATPase for muscle fibre type analysis
Slides were incubated in an acidic pre-incubation solution (0.49% Potassium
Acetate, 0.26% calcium chloride dihydrate, pH 4.38 adjusted with glacial acetic acid) for
7 minutes at room temperature, then washed 3 times for 2 minutes each in 0.1 Tris
Buffer. Slides were then incubated for 30 minutes at room temperature in an ATP
incubation solution, then rinsed in a 1% calcium chloride dihydrate solution. Slides were
stained in 0.1% toluidine blue for 90 seconds, cleared in running ddH2O, dehydrated in
ascending alcohols, and then cleared with xylenes. Slides were mounted in toluene-based
mounting media. Type I muscle fibres stained dark blue, type IIa fibres stained light blue,
and type IIb fibres stained white (see Figure 4b for an example).
2.2.6.3 Glycogen Periodic Acid Schiff for glycogen staining
Slides were placed directly in Carnoy’s fixative (ethanol, chloroform + glacial
acetic acid) at -30°C for 5-10 minutes, then removed from the freezer and allowed to
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continue to incubate while returning to room temperature. Once at room temperature, the
Carnoy’s fixative was discarded and the slides were rinsed in 3 changes of ddH2O, before
being placed in 0.5% periodic acid solution for 5 minutes at room temperature. Slides
were then left to incubate in 37.5°C Schiff’s reagent for 30 minutes, and then cleared
with running 37°C tap water for 10 minutes. Slides were then dehydrated in ascending
alcohols, cleared with xylenes, and mounted with toluene-based mounting media. Fibres
containing high glycogen stores stained a bright purple, while those with low glycogen
stores stained white (see Figure 4c for an example).
2.2.6.4 Oil Red O for quantification of neutral lipids
Muscle sections were surrounded by an immunoedge pen barrier and covered
with 0.5% Oil Red O solution in propylene glycol. Slides were left to incubate for 5 hours
in a humidity chamber at which point they were washed in running ddH2O and mounted
with aqueous mounting media (10% PBS, 90% glycerol). Fibres with high IMCL stores
stained dark reddish/brown, while those with low IMCL stores were a lightpinkish/yellow colour in comparison (see Figure 4d for an example).
2.2.7 Microscopy Image Collection and Muscle Fibre Analysis
All microscopic imaging was performed on a Zeiss AxioVert S100 microscope
equipped with a Canon EOS Rebel T2i camera adapted for use with an NDPL-1(2x)
attachment. Muscle sections were captured at 10x magnification in a grid pattern so that
each region of each slide was photographed, allowing the same region to be compared
between each of the histochemical slides.
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The grid photographs were printed and quantified, ensuring the same fibres were
examined across each stain. Fibre numbers were tallied so that a minimum of 200 fibres
were included per animal, with each of the fibres containing data from four different
stains (H/E, fibre type, Fat content, glycogen content). High/low IMCL/glycogen storage
content and muscle fibre identity were evaluated based on staining colour specific to each
procedure, as outlined in Methods section 2.2.6, Histochemical Analysis. Muscle fibres
were only included if they were clearly defined across all four stains, with a clear
distinction between those fibres containing high IMCL/glycogen stores versus those with
low stores, and clear distinction between fibre type, so as to avoid incomplete or
imprecise analysis.
2.2.8 Data Analysis
Muscle fibre type, fibre glycogen content, and fibre IMCL content were compared
within and between groups using a one-way analysis of variance (ANOVA) with
GraphPad Prism 6 (GraphPad Software, Inc.). When significant differences were
observed, pairwise post-hoc analysis was performed using the Tukey test. For results
demonstrating a significant Brown-Forsythe test for equality of group variances, post-hoc
analysis was performed using the Welch’s ANOVA for unequal variances. Significance
was determined for an alpha value of 0.05.
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2.3 Results
2.3.1 Animal Characteristics
Animal physical characteristics included weekly blood glucose (mmol/L) and
weekly body mass (g) measures. Complete body weight and blood glucose data were
collected for 17 animals (CS n=4; DCT n=4; DIT n=5; DCE n=4). These results are
presented in Figure 2 and Figure 3 respectively. Weekly glucose measures were
significantly different between all groups (P£0.0001) except for DCT vs. DCE, for which
no significant difference was found (Figure 2). These measurements were taken on nonfasted animals at 9:00 am, and through adjusting the number of insulin pellets implanted
in the animals, attempts were made to maintain DCT animals within blood glucose levels
between 9-15mmol/L, and DIT animals within 7-9mmol/L, respectively. Weekly body
mass analysis identified a significant difference between the DIT and DCE groups
(P=0.0059), although no other significant differences between the diabetic groups (DCT,
DIT, and DCE) were identified. The body mass for all three diabetic groups was
significantly lower than the mass of the CS animals (P<0.0001) (Figure 3).
2.3.2 Muscle Fibre Analysis Overview
A total of 14,520 skeletal muscle fibres were quantified across the four groups,
resulting in full profile information about muscle fibre type, IMCL content, glycogen
storage content, and tissue quality/context for 3,630 fibres, ranging from the fewest
completely quantifiable fibres in the DCT group (803), to the greatest number of
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completely quantifiable fibres in the DIT group (1,043). Histochemical analysis examples
are demonstrated in Figure 4.
2.3.3 Diabetes, Exercise, and Insulin Treatment Protocol induced changes to Type I fibres
With respect to the animals in the DIT group, there was a significantly greater
percentage of type I fibres containing high IMCL in both the CS and DCT groups
(P<0.0001), as well as the DCE group (P=0.0003) (Figure 5a). There were also a
significantly smaller number of these high IMCL type I fibres in the DCE group when
compared to CS (P=0.0047) (Figure 5a). No other significant differences were observed
between groups with respect to the percentage of type I fibres containing high IMCL
stores. No significant differences were observed between all groups with regards to the
percentage of type I fibres containing high glycogen stores (Figure 5b).
When compared to CS animals, there was a significantly higher percentage of
type I fibres found in both the DIT group (P=0.0017) and the DCE group (P=0.0445)
(Figure 5c). The animals in the DCT group also had significantly smaller percentage of
type I fibres than the animals in the DIT group (P=0.0104) (Figure 5c). No other
significant differences were observed between groups with respect to the overall
percentage of type I fibres analyzed within the muscle sections.
2.3.4 Diabetes, Exercise, and Insulin Treatment Protocol induced changes to Type IIa
fibres
There were no significant differences observed between all groups with regards to
the percentage of type IIa fibres containing high IMCL stores (Figure 6a). It was
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observed that the animals in the DIT group had a significantly higher percentage of type
IIa fibres containing high glycogen stores than the CS animals (P<0.0001) (Figure 6b).
No other significant differences were observed between groups with respect to the
percentage of type IIa fibres containing high glycogen stores. There were no significant
differences observed with regards to the overall percentage of type IIa fibres analyzed
between all groups (Figure 6a).
2.3.5 Diabetes, Exercise, and Insulin Treatment Protocol induced changes to Type IIb
fibres
There were no significant differences observed between all groups with regards to
the percentage of type IIb fibres containing high IMCL stores (Figure 7a), type IIb fibres
containing high glycogen stores (Figure 7b), or the overall percentage of type IIb fibres
analyzed (Figure 7c).
2.3.6 Diabetes, Exercise, and Insulin Treatment Protocol induced changes to Overall
Muscle Fibre profile
With respect to the animals in the DCE group, there was a significantly lower
percentage of high IMCL-containing muscle fibres in both the CS and DIT groups
(P=0.0002), as well as the DCT group (P=0.0094) (Figure 8a). No other significant
differences were observed between groups with respect to the overall percentage of fibres
containing high IMCL stores. There were no significant differences observed between all
groups with regards to the percentages of muscle fibres containing high glycogen content
(Figure 8b).

48

CS
DCT
DIT
DCE

20
15

*

10
5
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Blood Glucose (mmol/L)

Weekly Blood Glucose
25

Week

Figure 2: Mean non-fasted weekly blood glucose measures (mmol/L). All data presented
as mean ± SEM. * denotes P£ 0.0001.
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Figure 3: Mean weekly body mass measures (g). All data presented as mean ± SEM. *
denotes P=0.0059, ** denotes P<0.0001.
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Figure 4: Histochemical stains used in quantification, from left to right: (a) Hematoxylin
and Eosin (context stain used to help identify fibres), (b) Metachromatic myosin ATPase
(stain to identify muscle fibre type), (c) Glycogen Periodic Acid Schiff (stain to identify
high/low glycogen content), and (d) Oil Red O (stain for high/low IMCL content). See
Appendix G for quantification example.
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Figure 5: (a) The percentage of total type I fibres identified as containing high neutral
IMCL stores via Oil Red O staining. (b) The percentage of total type I fibres identified as
containing high glycogen stores via glycogen periodic acid Schiff staining. (c) The
percentage of total muscle fibres identified as type I via metachromatic myosin ATPase
staining. All data are expressed as mean ± SEM. * denotes 0.05>P>0.005; ** denotes
P=0.0047; *** denotes P=0.0017; **** denotes P=0.0003; ***** denotes P<0.0001.
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Figure 6: (a) The percentage of type IIa fibres identified as containing high neutral
IMCL stores via Oil Red O staining. (b) The percentage of total type IIa fibres identified
as containing high glycogen stores via glycogen periodic acid Schiff staining. (c) The
percentage of total muscle fibres identified as type IIa via metachromatic myosin ATPase
staining. All data are expressed as mean ± SEM. **** denotes P<0.0001.

52

Figure 7: (a) The percentage of total type IIb fibres identified as containing high neutral
IMCL stores via Oil Red O staining. (b) The percentage of total type IIb fibres identified
as containing high glycogen stores via glycogen periodic acid Schiff staining. (c) The
percentage of total muscle fibres identified as type IIb via metachromatic myosin ATPase
staining. All data are expressed as mean ± SEM.
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Figure 8: (a) The percentage of total fibres across all fibre types identified as containing
high neutral IMCL stores via Oil Red O staining. (b) The percentage of total muscle
fibres across all fibre types identified as containing high glycogen stores via glycogen
periodic acid Schiff staining. All data are expressed as mean ± SEM. ** denotes
P=0.0094; *** denotes P=0.0002.
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2.4 Discussion
It is well known that both T1DM and exercise place unique energetic demands
upon skeletal muscle as a whole; however, the mechanisms by which the various muscle
fibre types adapt to meet the combination of these energetic demands remains to be
understood. A limitation of previous research examining diabetic skeletal muscle health
and function is that most studies have only examined whole muscle physiology, rather
than investigating the differences between individual fibre types. Given that skeletal
muscle fibres vary drastically in their metabolic profiles, their relative energy substrate
usage, and their response to exercise, we set out to determine how a combined endurance
and resistance exercise training regimen would compare with the standard treatment of
care for patients with T1DM (intensive insulin treatment). Specifically, we wanted to
examine how T1DM impacts muscle fibre composition and energy substrate storage, and
how these transitions adapt following a 12-weeks exercise intervention.
First, we hypothesized that a regimen of intensive insulin treatment of T1DM rats
would cause a shift in muscle fibre type towards a higher percentage of type IIb fibres
with high intramuscular lipid (IMCL) stores. Second, we hypothesized that a combined
aerobic and anaerobic exercise training regimen would reduce IMCL stores in type IIb
fibres, shifting fibre type composition back towards a more oxidative type IIa profile.
Interestingly, results from the current investigation have demonstrated that only the type I
muscle fibres showed any significant changes in IMCL storage, whereas neither type IIa
nor type IIb fibres displayed the predicted changes postulated in our hypothesis.
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Although the percentage of overall high fat fibres was not different between CS
and DCT groups, both had significantly more high-fat fibres than the DIT group (Figure
5a). One possible explanation for this observation stems from work done previously by
our lab, where it was demonstrated that T1DM rats treated with intensive insulin therapy
had reduced skeletal muscle lipid content in conjunction with improved IR when
compared to conventional insulin treatment. This improvement in IR with intensive
insulin therapy is believed to be primarily due to a reduction in diacylglycerol (DAG) in
skeletal muscle fibres 37. However, the Oil Red O procedure stains all neutral lipids, and
cannot distinguish between DAG, triacylglycerol (TAG), and other neutral lipids. It is
plausible that in the current study, while a significant reduction in the accumulation of
DAG and other disruptive neutral lipid species may have occurred, the DIT group may
have maintained its stores of TAG, an energy-rich IMCL species that does not inhibit
insulin signalling 38.
In contrast, the type I fibres in the DCE group had significantly more IMCL stores
than those in the DIT group (Figure 5a). While this finding did not support our
hypothesis, it has been documented that exercise in non-diabetic patients leads to
increases in IMCL storage 39. This observation lends support for the Athlete’s Paradox,
the phenomenon in which exercise training leads to an increase in muscle IMCL
accompanied by improved metabolic indicators, such as improved insulin sensitivity.
Combining this observation with this investigation’s findings on fibre-specific data and
IMCL storage demonstrates that the Athlete’s Paradox likely occurs in T1DM rats
primarily because of the changes in type I fibres. In support of these findings, it has
recently been shown that trained healthy patients also increase their IMCL storage
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primarily in the type I fibres, which are well equipped to handle this change and thereby
allow the muscle to benefit from the increased IMCL stores 40.
Our data support the theory that lipotoxicity-induced IR may well be muscle fibre
type dependent. It is accepted that intramuscular triglycerides are primarily contained and
used within type I muscle fibres, a conclusion which is supported by the observation that
intramuscular triglyceride content is three times higher in type I oxidative fibres than in
type IIb glycolytic fibres 47. This suggests that lipid toxicity (and by extension lipid
metabolism-induced IR) is more closely associated with and may be more dependent on
type I muscle fibres than type II fibres 45. The data from the current study has shown that
the only changes in IMCL storage in T1DM occur within the type I fibres, and therefore
any change in lipid-based IR would likely stem from the differences found within these
fibres.
The current study also examined muscle IMCL and glycogen content without
mapping either energy store to specific fibre types (Figures 8a and 8b, respectively).
Although there were no differences observed regarding whole muscle glycogen stores
between groups (Figure 8b), whole-muscle IMCL stores in the DCE group were
significantly greater than those in any other group. Indeed, these results are in agreement
with a number of previous studies that showed an association between exercise training
and significant increases in IMCL storage 18,39,40.
In the current study, the only significant difference observed in muscle glycogen
storage was between CS and DIT type IIa fast-twitch oxidative fibres (Figure 6b).
Muscle glycogen is stored in the cytosol of the muscle fibre, so it is readily available as a
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fuel source for the contractile filaments 35. Previous studies have found that muscle
glycogen storage did not change significantly between intensive insulin treated T1DM
patients and healthy controls 35,48, although these studies did not examine muscle
glycogen storage in specific fibre types. With exercise training, both glycolytic and
oxidative enzyme activity have been shown to increase, though whole muscle glycogen
storage remained unchanged, pre-training and post-training 35. This earlier research
shows that whole muscle glycogen storage is relatively unaffected by exercise training,
though the data from the present study shows that while this phenomenon may apply to
skeletal muscle as a whole, individual type IIa muscle fibres may be susceptible to
change under intensive insulin treatment and T1DM.
Finally, when looking at the overall muscle fibre profile of the four study groups,
we identified significant differences in the percent of total fibres that stained as type I
fibres between the various groups (Fig 3), but no differences between the relative
percentage of type IIa (Fig 6) or type IIb fibres (Fig 9). Preliminary data from our lab has
shown that there is no evident change in the percentage of type IIa and IIb fibres, though
type II fibres may increase cross-sectional area and expression of hybrid muscle fibre
myosin heavy chain isoforms in response to diabetes and exercise 27. This preliminary
work is supported by the current study, where there was also no observed difference in
relative percentage of type IIa and IIb fibres seen. Future research into the changing
energy storage capacity of these T1DM hybrid myofibers could yield interesting results
and would help to further elucidate our understanding of T1DM skeletal muscle
metabolism.
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2.5 Conclusion
In conclusion, this study has demonstrated evidence against the hypothesis that
the changes within the skeletal muscle are due to shifting fibre type rather than
subcellular improvements to IMCL metabolism. We hypothesized that a regimen of
intensive insulin treatment would cause a shift in muscle fibre type towards a higher
percentage of type IIb fibres with high IMCL stores. Secondly, we hypothesized that a
combined aerobic and resistance exercise training regimen would lead to a reduction in
IMCL stores in type IIb fibres coupled with a shift towards more type I and IIa oxidative
fibres. Instead we found that there was no change within the type IIb fibres, and that the
fat storage mechanisms within type I skeletal muscle fibres were preferentially reduced
by the presence of T1DM and intensive insulin therapy. This finding was also evident in
the conventionally-treated sedentary animals but was readily improved with a 12-week
regimen of combined exercise training. These changes occurred within type I fibres only,
implying that instead of being caused by a shift between type IIa and IIb fibres, much of
the skeletal muscle-related dysfunction occurring in T1DM can likely be traced to
malfunctioning fat metabolism specifically within the type I fibre.
The current study provides support for the recommendation that patients with
T1DM, and especially those with “double diabetes”, may benefit by supplementing their
insulin treatment with a regular exercise training regimen consisting of both aerobic and
resistance exercise in order to improve insulin sensitivity. This investigation also
provides evidence to improve future efforts to mitigate the IMCL-related dysfunction
within the skeletal muscle by focusing on improving oxidative capacity specifically
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within the type I muscle fibre. This observation allows for identification of the type I
myofiber as a possible target for interventions specifically tailored to improve IMCL
storage within the fibre, including pharmacological and exercise treatments focused on
improving mitochondrial biogenesis, morphology, and density to divert fatty acids away
from storage and into oxidation. Future directed efforts to study the reduction of IR in
T1DM would benefit from metabolomic analysis of the type I myofiber IMCL stores in
conjunction with mitochondrial LD analysis, helping to further elucidate the fibrespecific adaptations to exercise and the intensity of insulin therapy within T1DM skeletal
muscle.
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Appendices
Appendix A: Multiple Low-dose Streptozotocin Induction
PURPOSE: To induce Type I diabetes in rats
MATERIALS: Gloves Lab Coat Streptozotocin (STZ) 5X Stock Citric Acid/Citrate
Buffer - Anhydrous Citric Acid - Sodium Citrate Dihydrate - MilliQ Deionized Water
13M HCl 3 Falcon Tubes Sterile Filter
EQUIPMENT: Biological Safety Cabinet Weigh Scale pH Meter
PROCEDURE:
Preparing 5X Citric Acid/Citrate Buffer
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add:
a. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate
b. 23.8g Sodium Citrate Dihydrate (Sigma), Mix into…
c. 175mL of MilliQ water The pH should be at 4.6, Add HCl or NaOH to
adjust (do not over-shoot pH)
2. Once the proper pH is obtained, add MilliQ water until you are close to the 200
ml mark (pH will move slightly). If satisfied with the pH, adjust volume in a 250
ml graduated cylinder and filter in a 0.2µm filter.
3. Store at room temperature. This is your 5X stock solution.
Making up Streptozotocin (STZ) for Injection **NOTE Animals should be pre-weighed
prior to making up STZ to ensure accurate amounts of STZ to be prepared.
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1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL
of distilled water filtered through a 0.2µm syringe filter. Check the pH. This gives
you a working concentration of 153 mM
2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of
concentrated HCl to the buffer, checking pH in between until desired pH is
reached. 3. Once pH is reached, add 1 mL distilled water (sterile filtered through a
0.2µm syringe filter as before). If pH is below 4.5, restart. 4. Weigh out an
appropriate amount of STZ for the number of animals (see calculations below)
that will be injected in a 15-minute time frame. Ex. Rats will be injected at
20mg/kg, so for 10 animals at an ideal weight of 200g (avg. weight of rats to be
injected), you will require a minimum of 40mg. 20mg/kg X 0.2kg = 4mg per
animal
3. The amount of STZ weighed out should be more than the minimum as some
solution will be lost in filtering. (4mg (per animal) X 12 rats = 48mg total
(0.048g) 5. Dissolve the STZ into buffer (keeping in mind a comfortable injection
volume). Shake to dissolve powder (approx. 1min). Sterile filter using a 0.2µm
syringe filter. Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution 4mg ÷ 16mg/mL
solution = 0.25mL 6. STZ is time dependent and must be used within 15 minutes
4. Injecting and Follow-Up of the Animals 1. Promptly inject each rat with the
solution (intraperitoneal) at a dosage rate of 20mg/mL (in this example, 0.25mL).
Do not use anymore STZ solution more than 15 minutes after it has been
dissolved in the sodium citrate buffer. 2. Dispose of any container having come
into contact with the STZ (in either powder or dissolved form) into a
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biohazardous waste receptacle. Dispose of needles into a sharps container. 3.
Return injected rats to their cage. Record the date of STZ injection and add a
biohazard label to the cage (leave biohazard label on cage for at least 3 days
following the last injection). 4. Repeat this procedure the following day. 5. Check
blood glucose daily. Diabetes is achieved with two non-fasting blood glucose
readings of >18 mmol Diabetes should be achieved after 5-8 injections (i.p.
20mg/kg).
REFERENCES: Low dose STZ induction protocol. Animal Models of Diabetic
Complications Consortium AMDCC Protocols. 2003
O’Brien BA, Harmon B V, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for
the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178:
176–181, 1996.
Melling CWJ, Grisé KN, Hasilo CP, Fier B, Milne KJ, Karmazyn M, Noble EG. A model
of poorly controlled type 1 diabetes mellitus and its treatment with aerobic exercise
training. Diabetes Metab 39: 226–235, 2013.
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Appendix B: Insulin Pellet Implantation
Pellet implantation (for a rat):
1. Anesthetize the animal using the isoflurane machine by placing it in the induction
chamber. Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open the
stopcock valve so gas reaches the chamber. Keep in chamber until the animal is
unconscious.
2. Remove the animal and place its nose in the nose cone, reduce the isoflurane to
3% to maintain the plane of anesthesia.
3. Shave the area where the pellet is to be implanted.
4. Using gauze (or a swab), apply 10% povidone-iodine solution to the skin,
followed by 70% ethanol, to disinfect the site of insertion.
5. Hold the skin with forceps and make a subcutaneous incision.
6. Cleanse a 12g trocar with 10% povidone-iodine solution and insert it through the
puncture site to a depth of at least 2 cm.
7. Using forceps, briefly immerse the pellet in 10% povidone-iodine solution, rinse
with saline and insert into the subcutaneous region.
8. Use 1 pellet for the first 350g of body weight.
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 %
povidone-iodine solution over the opening.
10. Close the incision by suturing.
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
12. Record on the cage card that insulin pellets have been implanted.
Pellet removal:
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1. Anesthetize the animal as described above for implantation.
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by
applying 10% povidone-iodine solution followed by 70% ethanol.
3. Using a scalpel (or scissors), make an incision through the skin superficial to the
location of the pellets.
4. Using forceps, remove the pellet. Some connective tissue may need to be cut
away using scissors. Discard the pellet.
5. Close the incision by suturing.
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
7. Record on the cage card that the pellets have been removed.

Appendix C: Histochemical Procedures – Hematoxylin and Eosin
•

Alkaline Tap water substitute
o 0.35g sodium bicarbonate
o 2.0g magnesium sulphate
o 100mL distilled water

•

Harris Haematoxylin (prepared commercially)

•

Acid Alcohol
o 1% HCL – 5mL
o 70% EtOH
§

346.5 mL EtOH

§

148.5 mL H2O
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•

1% Eosin Solution - stock

Procedure
1. Defrost frozen sections in humidity chamber for 1 hour
2. Hematoxylin for 20 min
3. Scott’s Tap water substitute – sections should end up purple blue
a. Rinse 5x
b. Fill for 1 min
c. Rinse 5x
4. Acid Alcohol 10 sec – sections should be reddish colour
5. Scott’s Tap water - sections should end up purple blue
a. Rinse 5x
b. Fill for 1 min
c. Rinse 5x
6. Eosin 3 min
7. Rinse with tap water 10-15 times to wash off surplus stain
8. Dehydrate
a. 65% EtOH 2 min
b. 80% EtOH 2 min
c. 95% EtOH 2 min
d. Anhydrous EtOH 2 min
e. Xylenes 1 min
9. Mount with toluene-based mounting media
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Appendix D: Histochemical Procedures - Metachromatic myosin ATPase
•

Acidic pre-incubation solution – 500 mL
o 0.49% KCH3COO (w/v) – 2.45g
o 0.26% CaCl2-2H2O (w/v) – 1.3g
o Adjust pH to 4.38 with glacial acetic acid immediately prior to use

•

0.1 Tris buffer
o 12.10g Trizma Base
o 2.60g CaCl2-2H2O
o Makes 1L – bring pH to 7.8 and double check pH EVERY time

•

ATP Incubation solution – 50 mL
o 0.4% glycine (w/v) ----------- 0.2g
o 0.42% CaCl2-2H2O (w/v) --- 0.21g
o 0.32% NaCl (w/v) ------------- 0.16g
o 0.19% NaOH (w/v) ----------- 0.095g
o 0.3% ATP (w/v) --------------- 0.15g
o Adjust pH to 9.4 with 5N HCL immediately prior to use
o Prepare this solution immediately prior to staining

•

1% Calcium Chloride Dihydrate Solution
o 10g CaCl2-2H2O
o Add to 1L ddH2O

•

0.1% Toluidine Blue solution
o 0.1% toluidine blue (w/v) for desired volume
o 125mL of ddH2O + 125mg toluidine blue
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o Mix well (vortex) before use
•

Dehydration solutions
o 95% EtOH
o 2x 100% EtOH
o 100% Xylenes

Procedure
1. Defrost frozen sections in humidity chamber for 1 hour
2. Prepare ATP incubation solution, adjust pH of Tris buffer and Acidic preincubation solution
3. Incubate slides for 7 min at room temperature in acidic pre-incubation solution
4. Wash 3x for 2min each in Tris buffer
5. Incubate for 30 min at room temperature in ATP incubation solution
6. Dip 4x in 3 changes of CaCl2-2H2O solution
7. Incubate for 90 seconds in 0.1% toluidine blue solution
8. Rinse in running ddH2O for 30 sec max – just make sure the excess is gone
9. Dip 5x in 95% EtOH
10. Dip 5x each in 2 changes of 100% EtOH
11. Incubate for 1 min in Xylenes
12. Mount with permount (toluene based mounting medium)
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Appendix E: Histochemical Procedures – Oil Red O
Procedure
1. Defrost frozen sections in humidity chamber for 1 hour
2. Circle each section on slide with Immunoedge pen (or wax pencil)
3. Drop 0.5% Oil Red O in propylene glycol solution on the section until it’s
completely covered
4. Incubate for 5 hours in closed humidity chamber
5. Wash with running ddH2O
6. Mount with aqueous mounting media

Appendix F: Histochemical Procedures – Glycogen Periodic Acid Schiff
•

Carnoy’s Fixative
o 95-100% EtOH

6.4mL

o Chloroform

1.2mL

o Glacial acetic acid 0.4mL
•

Periodic Acid Solution – make up fresh
o Periodic Acid (H5IO6) 0.05g
o Distilled H2O

•

10 mL

Schiff’s Reagent - stock – Fischer/Sigma

Procedure
1. Put Schiff’s reagent in 37.5°C water bath to warm up (need ~80mL)
2. Make Periodic Acid solution, and allow to warm up to room temp
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a. 0.5g Periodic Acid
b. 100mL Distilled Water
3. Make up Carnoy’s Fixative in the fume hood, then put in the fridge (in copland
jar)
a. 6.4 mL 95-100% EtOH
b. 1.2 mL Chloroform
c. 0.4 mL Glacial Acetic Acid
4. Put cut sections into Carnoy’s in copland jar in fridge for 5-10 min
5. Take out and allow the copland jar to come to room temperature (covered/in fume
hood, on stirrer, low)
6. Discard Carnoy’s, rinse 3x in 3 changes of ddH2O (copland jar w/slides + beaker,
ddH2O back and forth 3 times, then change. Rpt 3x)
7. Add Periodic Acid solution for 5 min @ room temperature
8. Discard Periodic Acid solution, rinse in ddH2O 3x
9. Add Schiff’s reagent for ~30min @ 37.5° in water bath (stirring low)
10. Discard Schiff’s carefully (it stains!!), run in 37° tap water for ~30 min ( until
water is not pink)
11. Dehydrate
a. 3 min in 65% EtOH
b. 2 min in 80% EtOH
c. 2 min in 95% EtOH
d. 2 min in 100% EtOH
e. 1 min in Xylenes
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12. Mount with toluene-based media

Appendix G: Quantification Example
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Quantification consisted of identifying the exact same fibre across all four stains,
ensuring there was a clear distinction between high/low and fibre type, and then using a
tally sheet to collect data.

Appendix H: Ethics Approval
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